跳至主要内容
临床试验/NCT00883506
NCT00883506已完成1 期

Randomized, 3-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions Under Fasting and Fed Conditions.

Sandoz0 个研究点目标入组 24 人开始时间: 2000年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Sandoz
入组人数
24
主要终点
Bioequivalence based on AUC and Cmax

研究概览

简要总结

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet under Fasting and Fed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

排除标准

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.

研究组 & 干预措施

1

Experimental

Lisinopril 40 mg Tablet under fed conditions.

干预措施: Lisinopril 40 mg Tablet under fed conditions. (Drug)

2

Active Comparator

Lisinopril 40 mg Tablet (Zestril)

干预措施: Lisinopril 40 mg Tablet (Zestril) under fed conditions. (Drug)

3

Experimental

Lisinopril 40 mg Tablet under fasting conditions.

干预措施: Lisinopril 40 mg Tablet under fasting conditions. (Drug)

结局指标

主要结局

Bioequivalence based on AUC and Cmax

时间窗: 50 days

次要结局

未报告次要终点

研究者

发起方
Sandoz
申办方类型
Industry

相似试验